X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (412) 412
humans (348) 348
hepatitis c (324) 324
hepatitis c virus (273) 273
gastroenterology & hepatology (265) 265
antiviral agents - therapeutic use (256) 256
hepatitis c, chronic - drug therapy (239) 239
ribavirin (214) 214
hepatitis (198) 198
interferon (193) 193
sofosbuvir (169) 169
drug therapy, combination (164) 164
male (161) 161
hepacivirus - genetics (160) 160
middle aged (160) 160
female (158) 158
sustained virological response (153) 153
genotype (151) 151
cirrhosis (145) 145
plus ribavirin (145) 145
antiviral agents (134) 134
treatment outcome (133) 133
virus-infection (133) 133
treatment-naive patients (130) 130
health aspects (126) 126
hcv (114) 114
liver (112) 112
patients (111) 111
genotype 1 infection (108) 108
ledipasvir (108) 108
adult (104) 104
pharmacology & pharmacy (104) 104
liver cirrhosis (103) 103
open-label (103) 103
therapy (103) 103
hepatitis c - drug therapy (99) 99
aged (97) 97
antiviral agents - administration & dosage (97) 97
antiviral agents - adverse effects (96) 96
sofosbuvir plus ribavirin (96) 96
hepacivirus - drug effects (95) 95
infections (93) 93
care and treatment (92) 92
ribavirin - therapeutic use (92) 92
biological response modifiers (89) 89
pegylated interferon (85) 85
infection (83) 83
infectious diseases (83) 83
hepatitis c, chronic - virology (81) 81
daclatasvir (79) 79
daclatasvir plus sofosbuvir (79) 79
analysis (78) 78
sofosbuvir - therapeutic use (78) 78
genotype 1 (77) 77
drug therapy (74) 74
sustained virologic response (73) 73
treatment-naive (73) 73
genotype & phenotype (72) 72
liver transplantation (72) 72
virus diseases (71) 71
viruses (71) 71
plus sofosbuvir (67) 67
simeprevir (67) 67
genotypes (65) 65
hcv infection (65) 65
direct-acting antivirals (63) 63
virology (62) 62
hepatitis c, chronic - complications (61) 61
treatment-experienced patients (61) 61
transplantation (60) 60
hepatology (55) 55
genetic aspects (53) 53
chronic infection (51) 51
hcv genotype 1 (51) 51
antiviral therapy (49) 49
liver diseases (49) 49
efficacy (48) 48
hepatitis-c virus (48) 48
safety (48) 48
chronic hepatitis-c (46) 46
clinical trials (46) 46
gastroenterology and hepatology (46) 46
hiv (46) 46
liver cirrhosis - virology (46) 46
sofosbuvir - administration & dosage (46) 46
medical research (45) 45
retrospective studies (45) 45
medicine & public health (44) 44
protease inhibitors (43) 43
human immunodeficiency virus--hiv (42) 42
liver cirrhosis - drug therapy (42) 42
hepatitis c - virology (41) 41
recurrence (41) 41
advanced liver-disease (40) 40
imidazoles - therapeutic use (40) 40
surgery (40) 40
chronic hcv (39) 39
double-blind (39) 39
hepacivirus (39) 39
hepatocellular-carcinoma (39) 39
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Seminars in Liver Disease, ISSN 0272-8087, 07/2019, Volume 39, Issue 3, pp. 354 - 368
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 03/2015, Volume 41, Issue 6, pp. 544 - 563
Summary Background An all‐oral, pegylated interferon (pegIFN)‐free and ribavirin (RBV)‐free single‐tablet of ledipasvir (LDV) and sofosbuvir (SOF) is now... 
SUSTAINED VIROLOGICAL RESPONSE | UNITED-STATES | HEPATOCELLULAR-CARCINOMA | CHRONIC HCV | PLUS SOFOSBUVIR | PEGYLATED INTERFERON | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | INTERFERON-ALPHA 2A | LIVER-DISEASE | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | Uridine Monophosphate - administration & dosage | Fluorenes - economics | Humans | Middle Aged | Fluorenes - therapeutic use | Hepacivirus - genetics | Male | Interferons - therapeutic use | Uridine Monophosphate - economics | Benzimidazoles - economics | Benzimidazoles - administration & dosage | Adult | Fluorenes - administration & dosage | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Quality-Adjusted Life Years | Hepacivirus - isolation & purification | Liver Cirrhosis - drug therapy | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Hepatitis C, Chronic - economics | Health Care Costs | Liver Cirrhosis - virology | Cost-Benefit Analysis | Uridine Monophosphate - analogs & derivatives | Antiviral Agents - economics | Protease inhibitors | Proteases | Analysis | Genetic aspects | Biological response modifiers | Hepatitis C virus | Health aspects | Liver cirrhosis
Journal Article
Journal Article
Journal Article
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, ISSN 0269-2813, 01/2019, Volume 49, Issue 1, pp. 99 - 106
Background Hepatitis C virus (HCV) genotype 6 (GT 6) is the predominant genotype among certain Asian populations. The availability of newer DAA options is... 
LDV plus SOF | VIRUS-INFECTION | hepatitis C | PREVALENCE | RIBAVIRIN | REGIMENS | INTERFERON | SOF plus VEL | sustained virological response | PHARMACOLOGY & PHARMACY | UPDATE | GASTROENTEROLOGY & HEPATOLOGY | cirrhosis | EPIDEMIOLOGY | genotype 6
Journal Article
Liver International, ISSN 1478-3223, 06/2018, Volume 38, Issue 6, pp. 1010 - 1021
Background & Aims We report data from two similarly designed studies that evaluated the efficacy, safety, and optimal duration of ledipasvir/sofosbuvir... 
ledipasvir | sofosbuvir | treatment‐experienced | HCV | HIV | treatment-experienced | PLUS RIBAVIRIN | LEDIPASVIR-SOFOSBUVIR | OPEN-LABEL | HCV INFECTION | CIRRHOSIS | GENOTYPE 1 INFECTION | GASTROENTEROLOGY & HEPATOLOGY | ADVANCED LIVER-DISEASE | PHASE-2 TRIAL | Uridine Monophosphate - administration & dosage | Headache - etiology | Coinfection - drug therapy | Humans | Middle Aged | Fatigue - etiology | Hepacivirus - genetics | Male | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Adult | Female | Fluorenes - administration & dosage | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | HIV Infections - virology | Liver Cirrhosis | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Coinfection - virology | Pregnancy | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | HIV Infections - drug therapy | Aged | Sustained Virologic Response | Headache | Medical research | Clinical trials | Viruses | Fatigue | Infections | Ribavirin | Cirrhosis | Hepatitis | Randomization | Inhibitors | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Adults | Interferon | Hepatitis C virus | Hepatitis C | Genotypes | Treatment-experienced | Sofosbuvir | Ledipasvir
Journal Article